Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | HPGD | P15428 | 4/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.67 |
| ▸ | CA7 | P43166 | 1/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4039721 | 0.94 | KMT2A (0.65) | ALDH1A1HPGDL3MBTL1CA12CA1 | |
| SCHEMBL9152022 | 0.92 | CA12 (0.77) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL4002999 | 0.87 | ALDH1A1 (0.75) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL27971693 | 0.87 | CA12 (0.70) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL12248114 | 0.85 | POLB (0.63) | ALDH1A1HPGDL3MBTL1KMT2APOLB | |
| SCHEMBL142197 | 0.85 | CA12 (0.68) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL4724436 | 0.85 | KMT2A (0.75) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL1877246 | 0.85 | KMT2A (0.80) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL15837506 | 0.84 | ALDH1A1 (0.68) | ALDH1A1HPGDL3MBTL1CA12CA1 | |
| SCHEMBL10724841 | 0.84 | POLB (0.81) | ALDH1A1HPGDL3MBTL1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009026422-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | WO | claimed |
| EP-4711366-A1 | PYRIMIDO MACROHETEROCYCLIC COMPOUND AS WEE1-YES DUAL-TARGET INHIBITOR AND USE THEREOF | Mindrank AI Ltd. (CN) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024230807-A1 | PYRIMIDO MACROHETEROCYCLIC COMPOUND AS WEE1-YES DUAL-TARGET INHIBITOR AND USE THEREOF | 杭州德睿智药科技有限公司 | 2024-11-14 | — | — | WO | disclosed |
| CN-114605329-B | Substituted indazole carboxamides or substituted azaindazole carboxamides FLT3 inhibitors and uses thereof | 河南中医药大学 | 2024-01-26 | — | — | CN | disclosed |
| CN-111566100-B | Pyrimidine compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2021236650-A1 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| US-20210101881-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2021-04-08 | — | — | US | disclosed |
| CN-111566100-A | Pyrimidine compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-10619028-B2 | Polyarylene fiber with improved hydrolytic stability | TEIJIN ARAMID B.V. (NL) | 2020-04-14 | — | — | US | disclosed |
| EP-1436291-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | Aventis Pharma S.A. (FR) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004026829-A2 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
| EP-1379501-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20030092756-A1 | Substituted indolinones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-05-15 | — | — | US | disclosed |
| WO-2003024967-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-03-27 | — | — | WO | disclosed |
| EP-1052248-B1 | Process for the preparation of aqueous solutions of diazonium salts | CLARIANT GMBH (DE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2002081445-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| US-6207809-B1 | CATALYTIC HYDROGENATION USING THE CORRESPONDING NITRO COMPOUND | CLARIANT GMBH (DE) | 2001-03-27 | — | — | US | disclosed |
| EP-1052248-A1 | Process for the preparation of aqueous solutions of diazonium salts | Clariant GmbH (DE) | 2000-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092756-A1 | Substituted indolinones | CDK1, CDK2, CDKL1 | ALDH1A1 1526/4885HPGD 1513/4885L3MBTL1 4747/4885 |
| US-10619028-B2 | Polyarylene fiber with improved hydrolytic stability | PAH, COMT, MAOB | ALDH1A1 1215/4885HPGD 1087/4885L3MBTL1 3061/4885 |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | CDK2, CCNI, CCNK | ALDH1A1 1264/4885HPGD 693/4885L3MBTL1 4029/4885 |
| US-20210101881-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | CDK9, CDK19, CDK6 | ALDH1A1 1509/4885HPGD 830/4885L3MBTL1 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.